These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16611263)

  • 1. Review article: hepatitis B and liver transplantation.
    Mutimer D
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1031-41. PubMed ID: 16611263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases].
    Seehofer D; Rayes N; Bechstein WO; Naumann U; Neuhaus R; Berg T; Hopf U; Langrehr JM; Steinmüller T; Platz KP; Müller AR; Neuhaus P
    Z Gastroenterol; 2000 Sep; 38(9):773-83. PubMed ID: 11072673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B.
    Keeffe EB
    J Med Virol; 2000 Jul; 61(3):403-8. PubMed ID: 10861654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatitis B in liver transplantation patients.
    Samuel D
    Semin Liver Dis; 2004; 24 Suppl 1():55-62. PubMed ID: 15192802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S; Ham MY; Stone MA; Holt C; Tong M
    Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors.
    Dodson SF
    Clin Transplant; 2000; 14 Suppl 2():20-4. PubMed ID: 10965960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lamivudine or tenofovir plus intramuscular hepatitis B immunoglobulin in prevention of hepatitis B virus reinfection after liver transplant.
    Nassiri-Toosi M; Kasraianfard A; Ahmadinejad Z; Dashti H; Moini M; Najafi A; Salimi J; Jafarian A
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():127-32. PubMed ID: 25894141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience.
    Bohorquez HE; Cohen AJ; Girgrah N; Bruce DS; Carmody IC; Joshi S; Reichman TW; Therapondos G; Mason AL; Loss GE
    Liver Transpl; 2013 Jun; 19(6):611-8. PubMed ID: 23526668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of entecavir in preventing hepatitis B recurrence after liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Wang X; Shen CH; Luo Y; Xin TY; Wang SY; Qiu DK
    J Dig Dis; 2009 Nov; 10(4):321-7. PubMed ID: 19906113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure.
    Liu CL; Fan ST; Lo CM; Wei WI; Yong BH; Lai CL; Wong J
    Transplantation; 2003 Oct; 76(8):1174-9. PubMed ID: 14578749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
    Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
    Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine.
    Jain A; Orloff M; Abt P; Kashyap R; Mohanka R; Lansing K; Kelley M; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3187-9. PubMed ID: 16213345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.